Unanticipated results from 2 recent candidate human immunodeficiency virus type 1 (HIV-1) vaccine regimens in large-scale international trials highlight the importance of understanding the optimal earliest immune defense against HIV-1 infection. Presented here are key findings in these vaccine studies with relevance to the development of future vaccines to control acute HIV-1 infection.
No takes yet. Share an insight, caveat, or question.
M. Juliana McElrath (2010) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: